To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
The upcoming expiry of the semaglutide patent in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...
MUMBAI: Natco Pharma has heralded what could become an intense pricing war in India’s pharmaceutical sector by offering its generic version of semaglutide at 90% cheaper than the original weight-loss ...
Kantipuly is a preventive medicine and public health resident at McGill University and visiting scholar at the University of New Mexico. Singer is VK Rajah visiting professor of medical ethics at the ...
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...
Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of Hormuz for the arrival of key inputs in drug manufacturing including petroleum-based materials, and for ...
Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. There is no established timeframe for forming a new ...
MUMBAI – A deluge of weight-loss drugs is set to transform the global fight against obesity, as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results